LithLover wrote: I've never understood any company waiting until the very last minute to file. The filing deadlines are set almost a year in advance. If you can't file a day or 2 early just to make sure everything is in, that's on the CEO.
https://www.osc.ca/en/industry/companies/reporting-issuer-and-issuer-forms/filing-due-dates-calendar-annual-and-interim-filings-reporting-issuers
That being said we have talked at nauseum about the mistake in the Aristotle roll out. Financials should have been out a day or 2 before quarter end, followed by the announcement of Aristotle and the need for a positive test process with the deal with Care Oncology all out together. Instead we got late filings, only a small piece of the roll out plan and so it was oversold and short attacked. That's the price you pay when you don't properly roll out the most important product in company history. Yes Tripp was ill prepared and failed to understand what the market wanted to know.
The toothpaste is now out of the tube. No going back.
But the bottom line is they made $3 million in revenue in Q4, will likely make more than that in Q1 (Monday May 17, maybe they file the Friday before - crazy huh). Think about that Q3 2020, Q4 2020 and Q1 2021 could be almost $10 million in revenues. That is a huge increase over last year and they have $7 million in the bank from previous financings. Now a LOI with Care Oncology and Aristotle testing started last Monday.
Step back and let that digest. Cashed up, testing starting, more cash coming in and plans to expand to employers. In any other situation this would be huge and a sea change for any company.
No matter what you think of the botched roll out, the market cap is undervalued at this level. Shorters are controlling the share price and investors and maybe even institutional investors are punishing Tripp for the misstep but the fundamentals are still all here. Maybe it lingers down here but soon we will get more updates and a juicy Q1 and it will come back up.
Even Noel has a target of $1.25 even though that's way down from the previous $4 but still up 50% from here. It will be over $1 again soon and back on track. Noel will update his target as we see revenues and updates coming in.
Absolutely no defence for Tripp's strategy or lack thereof - this was the biggest event in SZ's history, we had 3 months of silence to prepare for it and yet everything came out sideways, late and disappointing. The one clear catalyst was the $2.82 mil revenue - but it was put out after hours at the start of a long weekend - 101 stuff and unacceptable -ie:bungled badly and makes me wonder what might happen with the Q1 results NR to come.
It is becoming clear that for some reason investors are not reacting to strong quarterly earnings - most likely because they recognize covid is a shorter term phenomena. Ultimately its Aristotle and now AVPR and the new potential acquisition that represents the future. My fear now is that the deal does not/not go through as all effort and strategy is focussed on it. If in two months they notify its dead, then we start all over with nothing.
All of the above aside however, I agree with your assessment:
Step back and let that digest. Cashed up, testing starting, more cash coming in and plans to expand to employers. In any other situation this would be huge and a sea change for any company.
No matter what you think of the botched roll out, the market cap is undervalued at this level. Shorters are controlling the share price and investors and maybe even institutional investors are punishing Tripp for the misstep but the fundamentals are still all here. Maybe it lingers down here but soon we will get more updates and a juicy Q1 and it will come back up.